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JNKs are attractive targets for treatment of obesity and type-2
diabetes. A sustained increase in JNK activity was observed in
dietary and genetic models of obesity in mice, whereas JNK
deficiency prevented obesity-induced insulin resistance. A similar
insulin-sensitizing effect was seen upon treatment of obese mice
with JNK inhibitors. We now demonstrate that treatment with the
saturated fatty acid palmitic acid results in sustained JNK activation
and insulin resistance in primary mouse hepatocytes and pancre-
atic -cells. In the latter, palmitic acid treatment inhibits glucose-
induced insulin gene transcription, in part, by interfering with
autocrine insulin signaling through phosphorylation of insulin-
receptor substrates 1 and 2 at sites that interfere with binding to
activated insulin receptors. This mechanism may account for the
induction of central insulin resistance by free fatty acids.
diabetes  insulin gene expression  lipotoxicity  obesity
Type-2 diabetes mellitus is a metabolic disease of alarmingprevalence, affecting 170 million individuals worldwide in
2001, a number predicted to increase by almost 50% by 2010 (1).
Recent studies focused attention on JNK family members,
especially JNK1, as promising drug targets in the treatment of
obesity and type-2 diabetes (2–4). Sustained JNK activation was
observed in both dietary and genetic models of obesity (2),
whereas mice with a targeted mutation at the Jnk1 locus are
resistant to obesity-induced insulin resistance (2). Although
JNK1 isoforms are the major contributors to insulin resistance,
a recent study has shown that, upon reduction of the JNK1 dose,
JNK2 isoforms also contribute to glucose intolerance (3). The
proposed mechanism by which JNK activation leads to insulin
resistance is centered on the phosphorylation of insulin-receptor
substrate (IRS)1 at the inhibitory site Ser-307 (2, 5). Normally,
insulin receptor (InsR) activation induces IRS1 Tyr phosphor-
ylation, thereby triggering downstream signaling pathways, such
as the phosphatidylinositol 3-kinase (PI3K)-AKT cascade (6).
However, Ser-307 phosphorylation inhibits recruitment of IRS1
to the activated receptor by interfering with the function of its
phospho-Tyr-binding (PTB) motif, thereby preventing activa-
tion of PI3K-AKT signaling and other effector pathways (5, 7).
Ablation of the Jnk1 locus or treatment with a peptide inhibitor
of JNK (D-JNKi) prevents IRS1 Ser-307 phosphorylation and
potentiates InsR signaling (2, 4). In addition to improved InsR
signaling in peripheral insulin-responsive tissues (liver, muscle,
and adipose tissue), treatment with D-JNKi increases insulin
mRNA and protein content in pancreatic -cells of obese mice
(4). Furthermore, expression of catalytically inactive JNK in
cultured -cells prevents inhibition of insulin gene transcription
in response to oxidative stress (8). The inhibitory effect of
oxidative stress was suggested to be due to inhibition of AKT
activation, which eventually results in cytoplasmic accumulation
of PDX-1, a transcription factor that controls insulin gene
transcription (9).
Although IRS1 phosphorylation at Ser-307 correlates with,
and may account for, inhibition of AKT activation (2, 4),
complete absence of IRS1 results in only a mild diabetogenic
phenotype (10). Thus, it is likely that the absence of IRS1 is
compensated for by the related adaptor molecule IRS2 (11, 12),
suggesting that JNK activation may also lead to inhibition of
IRS2 functions. In fact, the relative contributions of IRS1 and
IRS2 to InsR signaling in liver was recently investigated by
adenovirus-mediated gene transfer of small interfering hairpin
RNAs (shRNA). That study demonstrated that silencing of
either IRS1 or IRS2 alone did not affect PI3K and AKT
activation, whereas delivery of shIRS1 plus shIRS2 adenoviruses
decreased activation of both effector functions (13).
Here, we propose that lipotoxicity is a major trigger of JNK
activation during obesity and show that long-chain saturated
fatty acids, such as palmitic acid (PA), can trigger insulin
resistance in both primary hepatocytes and pancreatic -cells in
a JNK-dependent manner. We also demonstrate that PA-
mediated inhibition of insulin gene induction by either glucose
or insulin is JNK-dependent and likely to be mediated through
IRS1 and IRS2 phosphorylation. Indeed, we have identified a
JNK phosphorylation site on IRS2 that may be functionally
equivalent to Ser-307 of IRS1.
Results
Obesity and Saturated Fatty Acids, but Not High Glucose, Lead to JNK
Activation.Obese mice exhibit sustained JNK activation (2). Two
major obesity-induced complications are glucotoxicity and lipo-
toxicity (14). To test whether glucotoxicity can lead to JNK
activation, we generated lean diabetic animals using a single
injection of streptozotocin (STZ) or alloxan, two different toxic
agents that induce insulin-dependent diabetes (15). STZ- or
alloxan-injected mice developed severe hyperglycemia 3 days
after injection that persisted for at least 10 days (Fig. 6, which is
published as supporting information on the PNAS web site).
Despite this profound effect, JNK activity in the liver was not
elevated (Fig. 1A). By contrast, genetically obese (obob) mice
or mice kept on high fat diet exhibited a substantial elevation of
JNK activity in their livers (Fig. 1A).
If high blood glucose does not lead to JNK activation, perhaps
this response is caused by blood lipids, such as free fatty acids
(FFA), whose concentration is also elevated in genetic and
dietary obesity (14). To examine this possibility we tested the
capacity of different FFA to activate JNK in primary hepato-
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cytes. The specific fatty acid to be examined (at 0.5 mM) was
bound to fatty acid-free BSA (0.5%) as described in Materials
and Methods. By and large, only modest effects on JNK activity
were observed upon incubation with BSA loaded with unsatur-
ated FFA, but incubation with BSA loaded with saturated FFA,
such as PA, resulted in substantial JNK activation after 1–2 h
(Fig. 1B; and see Fig. 7, which is published as supporting
information on the PNAS web site). Liver perfusion with PA
adsorbed to BSA also led to substantial JNK activation (Fig. 1C),
suggesting that saturated FFA also cause JNK activation in vivo.
PA Induces Insulin Resistance in Primary Hepatocytes in a JNK-
Dependent Manner. In addition to JNK activation, incubation of
primary hepatocytes with PA for 2 h inhibited insulin-induced
AKT activation (Fig. 2A) and led to IRS1 phosphorylation at the
inhibitory site Ser-307 (Fig. 2C). Treatment with the JNK
peptide inhibitor D-JNKi restored AKT activation (Fig. 2A) and
prevented PA-induced IRS1 Ser-307 phosphorylation (Fig. 2D).
Similar effects of PA were observed on insulin-induced PI3K
activity immunoprecipitated with antibodies to phosphotyrosine
(PY), IRS1, or IRS2 (Fig. 2B; and see Fig. 8, which is published
as supporting information on the PNAS web site).
As expected, hepatocytes from Jnk1/ mice were protected
from PA-induced IRS1 Ser-307 phosphorylation and PA-
induced inhibition of either PY-associated PI3K activity or AKT
activation by insulin (Fig. 9, which is published as supporting
information on the PNAS web site). Reconstitution of Jnk1/
hepatocytes with a lentivirus expressing JNK1 restored PA-
induced IRS1 Ser-307 phosphorylation and inhibition of the
PI3K–AKT cascade (Fig. 9).
PA Inhibits Glucose-Induced Insulin Gene Expression in a JNK-Depen-
dent Manner. Injection (i.p.) of obese mice with the peptide
inhibitor of JNK, D-JNKi, increased the pancreatic content of
insulin RNA and protein (4). In addition, infection of cultured
-cells with an adenovirus expressing a catalytically inactive
mutant of JNK prevented inhibition of insulin transcription by
H2O2 (8). Because PA is a more natural inhibitor of insulin
transcription (16–18) than H2O2, and the results shown above
demonstrated it to be a potent JNK activator, we examined
whether JNK mediates the inhibitory effect of PA on insulin
gene transcription. As seen in hepatocytes, PA incubation of
cultured mouse islets resulted in JNK activation within 30 (Fig.
3A). Longer incubation with PA (12 h) led to an even more
pronounced JNK activation, which was not affected by glucose
concentrations (Fig. 10, which is published as supporting infor-
mation on the PNAS web site). In the same experiment, we also
measured the cellular content of insulin mRNA by S1 nuclease
protection assay. Although PA did not affect insulin mRNA
abundance at substimulatory glucose concentrations (5.5 mM),
it severely impaired the induction of insulin gene transcription in
cells exposed to high glucose (16.7 mM). Moreover, wild type
islets treated with the JNK peptide inhibitor or islets from
Jnk1/ mice were protected from the inhibitory effects of PA
on insulin gene (Fig. 3B).
It had been reported that glucose-induced insulin gene tran-
scription requires autocrine insulin signaling (19–21). Insulin
mRNA induction by either glucose or insulin is blunted upon
deletion of InsR from -cells (21). PA also inhibited insulin-
induced insulin gene expression, and that effect was also pre-
vented upon incubation with the JNK peptide inhibitor (Fig. 3C).
Furthermore, no inhibition of insulin-induced insulin mRNA
Fig. 1. Free fatty acids and lipotoxic stress lead to sustained JNK activation.
(A) Comparison of JNK activity using a solid-state kinase assay and GST-cJun
(1–79) as a substrate in liver extracts from leannondiabetic, obese, and
leandiabetic mice. JNK1 levels were determined by immunoblotting. (B) JNK
kinase activity in lysates of primary hepatocytes treated for the indicated times
with delipidated BSA or BSA loaded with the indicated unsaturated (Left) or
saturated (Right) fatty acids. (C) JNK activity in livers of mice that were
perfused for 1 h with either delipidated or PA-loaded BSA.
Fig. 2. PA inhibits insulin signaling in primary mouse hepatocytes through
a JNK-dependent mechanism. (A) Effect of JNK inhibition on PA-induced
insulin resistance. Cells were incubated with or without PA (0.5 mM) for 2 h.
When indicated, the peptide inhibitor of JNK, D-JNKi, was added during PA
treatment before and 10 min after addition of insulin. AKT phosphorylation
was assessed by immunoblotting. (B) PA inhibits IRS1–2-associated PI3K activ-
ity. Primary hepatocytes were treated as above, and PI3K activity was sepa-
rately measured in PY, IRS1, and IRS2 immunoprecipitates. (C) Effects of PA on
IRS1 Ser-307 phosphorylation. Cells were treated with PA (0.5 mM) for the
indicated times before IRS1 Ser-307 phosphorylation was assessed by immu-
noblotting. (D) Effect of JNK inhibition on PA-induced IRS1 Ser-307 phosphor-
ylation. Cells were treated as above, except that D-JNKi was present during the
PA treatment.











was seen upon treatment of Jnk1/ islets with PA. As expected,
the JNK peptide inhibitor also prevented PA-induced IRS1
Ser-307 phosphorylation (Fig. 11, which is published as support-
ing information on the PNAS web site) and interfered with
inhibition of AKT activation (Fig. 3D).
Both IRS1 and IRS2 Are Involved in Induction of Insulin Gene Expres-
sion. Currently, the main molecular mechanism for JNK-induced
insulin resistance entails the phosphorylation of IRS1 at Ser-307,
which is located next to its PTBmotif (5). The PTBmotif increases
the affinity of IRS1 for the activated InsR (22–24), and Ser-307
phosphorylation interferes with this function (7, 22), thereby de-
creasing binding of IRS1 for the activated receptor (Fig. 4A).
However, a recent study using adenoviral vectors expressing small
hairpin interfering RNAs for IRS1 (shIRS1) or IRS2 (shIRS2)
showed that an 80% decrease in IRS1 expression did not inhibit
insulin-induced PI3K and AKT activation, whereas a concomitant
knockdown of both IRS1 and IRS2 resulted in a substantial
inhibition of PI3K and AKT activation (13).
To examine the contribution of IRS1 and IRS2 to insulin
signaling and insulin gene induction in -cells, we infected these
cells with adenoviruses expressing shIRS1, shIRS2, or GFP.
Infection of -cells with shIRS1 reduced IRS1 protein levels by
80%, whereas shIRS2 decreased the IRS2 amount by 60% (Fig.
4B). Infection of primary -cells with either the GFP virus or the
shIRS1 or shIRS2 viruses alone did not modulate insulin-
induced AKT phosphorylation and insulin gene induction (Fig.
4 B and C). However, coinfection with both shIRS1 and shIRS2
led to severe defects in insulin-induced AKT phosphorylation
and insulin gene induction (Fig. 4 B and C). These results
strongly suggest that IRS1 phosphorylation alone cannot ac-
count for the inhibitory effect of JNK on InsR signaling and that
an additional inhibitory effect is likely to be extended to IRS2.
JNK Phosphorylates IRS2.We next tested whether JNK can directly
phosphorylate IRS2 at a site that is functionally equivalent to
Ser-307 of IRS1. JNK-mediated phosphorylation depends on a
specific interaction with a docking site on its substrates called the
D domain and the presence of a Pro at the P 1 position relative
to the phosphoacceptor (P) site (25). Sequence alignment shows
that the D domain of IRS1 is fully conserved in IRS2 (Fig. 5A),
Although Ser-307 on IRS1 is not conserved in IRS2, sequence
alignment reveals a potential JNK phosphoacceptor site in IRS2
one amino acid before the one corresponding to IRS1 Ser-307;
in rat IRS2, this site corresponds to Thr-348 (Fig. 5A). Using
lysates of HEK293 expressing rat IRS2, we found that JNK1, but
not p38, bound to IRS2 in a manner sensitive to the JNK
peptide inhibitor, whose sequence corresponds to the D domain
of the JNK-interacting protein JIP1 (Fig. 5C). To test whether
JNK1 phosphorylates Thr-348, we subcloned a fragment of the
IRS2 cDNA containing the D domain and the putative JNK
phosphoacceptor site (IRS2JD), or amutant thereof in which the
Thr-348 codon was replaced by an Ala codon (IRS2JalaD), into
a bacterial GST-fusion protein expression vector.Whereas JNK1
readily phosphorylated the wild-type IRS2JD polypeptide, and
the phosphorylation was inhibited by the JNK inhibitor
SP600125, no phosphorylation of the IRS2JalaD mutant was
observed (Fig. 5B). To examine phosphorylation of IRS2JD in
living cells, we have cloned Flag-tagged IRS2JD and IRS2JalaD
in a mammalian expression vector. Coexpression of IRS2JD with
a constitutively active JNK1-JNKK2 fusion protein (26) resulted
in a leftward shift of IRS2JD on a 2D gel electrophoresis system,
indicating a decrease in its isoelectric point, a change that is
Fig. 3. Inhibition of insulin gene expression by PA is JNK-dependent. (A) Cultured mouse islets were incubated with PA for the indicated durations, and JNK
activity and abundance were determined by a kinase assay and immunoblotting, respectively. (B) S1 nuclease-protection assay. Cytoplasmic RNA was isolated
fromwt or Jnk1/ islets that were cultured in low (5.5 mM) or high (16.7 mM) glucose and treated with PA or D-JNKi as indicated for 12 h. Relative insulin mRNA
levels are indicated above the panel. (C) Palmitate inhibition of insulin-induced insulin transcription is JNK-dependent. wt or Jnk1/ islets were kept in low
glucose (5.5 mM). PA with or without D-JNKi was added 12 h before the addition of insulin. RNA was prepared 2 h later. Relative insulin mRNA levels are indicated
above the panel. (D) Immunoblot analysis of AKT Ser-473 phosphorylation. Primary mouse islets were treated with PA with or without D-JNKi, as above, and
treated with insulin for 5 min. AKT phosphorylation and abundance were measured by immunoblotting.
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consistent with phosphorylation (Fig. 5D). Treatment of cell
lysates with calf intestinal phosphatase increased the isoelectric
point of the protein, consistent with its dephosphorylation. No
shift in isoelectric point was observed upon coexpression of
IRS2JalaD with the activated JNK1 (Fig. 5D).
Discussion
The homeostatic control of blood glucose is determined by two
major factors: the concentration of insulin in the circulation and
insulin sensitivity of target organs (e.g., muscle, adipose tissue,
and liver). It is well accepted that, in obesity-induced diabetes,
insulin resistance progresses toward glucose intolerance and
type-2 diabetes because of increased demand for insulin and
eventual failure of pancreatic -cells to meet this demand (27).
Studies had demonstrated that JNK deficiency is protective in
different mouse models of obesity-induced glucose intolerance
because it increases the sensitivity of target tissues to insulin (2,
3). Yet, despite improved glucose tolerance and increased
peripheral insulin sensitivity, pharmacological intervention with
JNK activity was also found to increase the amount of insulin
mRNA and protein in pancreatic -cells (4, 8). The latter results
suggested that, in addition to its insulin tolerizing activity in
Fig. 4. Both IRS1 and IRS2 are involved in insulin-induced insulin gene
transcription in -cells. (A) The currently proposed mechanism of JNK action,
IRS1 Ser-307 phosphorylation, decreases the affinity of the IRS1 PTB domain
for activated InsR, thereby decreasing its tyrosine phosphorylation and ability
to activate various effector functions. IRS2 may compensate for loss of IRS1
function. (B) IRS1 and IRS2 are required for insulin-induced AKT phosphory-
lation in -cells. Cultured mouse islets were infected or not with Ad-shIRS1,
Ad-shIRS2, or an Ad-GFP control virus as indicated. After 24 h, the cells were
treated with insulin (200 microunitsml) for 5 min. AKT phosphorylation and
IRS1 and IRS2 expression were analyzed by immunoblotting. (C) IRS1 and IRS2
are required for insulin-induced insulin gene expression. Islets were treated as
above, and insulin mRNA abundance was examined 2 h after insulin addition.
Relative insulin mRNA levels are indicated above the panel.
Fig. 5. JNK1 binds to and phosphorylates rat IRS2 on Thr-348. (A) Schematic
representation of JNK-mediated IRS phosphorylation. Specificity is achieved
by specific docking and phosphorylation sites that are conserved between IRS1
and IRS2. (B) JNK1 phosphorylates IRS2 at Thr-348 in vitro. JNK kinase assay
was performed by coincubation of purified GSTJNK1 with its upstream kinase
GSTJNKK1 and either purified GSTIRS2JD or GSTIRS2JalaD as substrates. The
addition of the JNK inhibitor SP600125 was used as a specificity control. (C)
JNK1 specifically binds to IRS2. Lysates from HEK293T cells transfected with
pcDNA3-IRS2 were coincubated with purified GST-JNK1 in the presence or
absence of D-JNKi or with GST-p38 as a control. Glutathione-bead ‘‘pull-
downs’’ were analyzed by immunoblotting with IRS2-specific antibodies. (D)
JNK1 phosphorylates IRS2 at Thr-348 in living cells. HEK293T cells were trans-
fected with mammalian expression vectors expressing Flag-tagged IRS2JD or
IRS2JalaD with a vector encoding the constitutive active JNKK2–JNK1 fusion.
Protein extracts were analyzed by 2D gel electrophoresis and immunoblotting
with Flag antibodies. (E) A model illustrating the role of JNK in insulin
resistance caused by fatty acids and other stressors involved in obesity-induced
diabetes. Phosphorylation of IRS1 at Ser-307 and IRS2 at Thr-348 decreases
their binding and phosphorylation by the activated InsR. This decrease atten-
uates InsR signaling and prevents activation of effector functions.











peripheral tissues, JNK might also be involved in negative
regulation of insulin synthesis or signaling within the pancreatic
 cell, the central site of blood glucose regulation. In this study,
we examined the basis for JNK activation during obesity-induced
insulin resistance and the role of JNK in perturbation of -cell
function. Two major adverse outcomes of obesity-induced insu-
lin resistance are glucotoxicity and lipotoxicity. Our results
indicate that lipotoxicity because of increased blood FFA levels
or ectopic fat deposition is the most likely mediator of sustained
JNK activation in obese mice. Elevated blood glucose and
glucotoxicity alone do not result in JNK activation in peripheral
insulin-responsive tissues, such as the liver. Sustained JNK
activation in such tissues is of pathophysiological importance
because it interferes with insulin signaling, thereby leading to
insulin resistance and glucose intolerance (2, 4). Our results
show that, among different FFA, long-chain-saturated fatty
acids, such as PA, are the most potent activators of JNK in
cultured hepatocytes and -cells. These data are consistent with
recently published results showing that a mixture of FFA acti-
vates JNK in adipocytes (28) and that PA and stearic acid induce
JNK phosphorylation in primary hepatocytes (29).
Although the mechanisms leading to JNK activation by FFA
are unknown, its consequences are clear. Sustained JNK acti-
vation inhibits insulin signaling not only in hepatocytes and other
peripheral sites but also in pancreatic -cells, where it interferes
with glucose and insulin-induced insulin gene transcription.
Recently, JNK activation was also shown to be responsible for
the effects of H2O2 on insulin gene transcription by a mechanism
that involves inhibition of AKT activation, which is required for
phosphorylation of the stress- and nutrient-responsive transcrip-
tion factor Foxo1 (8, 9), resulting in enhanced nuclear retention
of Foxo-1, which negatively affects insulin gene transcription by
inhibiting PDX-1, a major activator of the insulin promoter (9).
Interestingly, PA treatment of -cells also decreases the nuclear
pool of PDX-1 (17, 18). We suggest that most of these effects are
consequences of JNK-mediated phosphorylation of IRS1 and
IRS2, which prevents InsR-proximal events. Using adenovirus-
mediated delivery of shRNA, we show that both IRS1 and IRS2
are required for insulin-induced AKT activation and insulin gene
transcription. Because the knockdown of IRS1 alone does not
disrupt either AKT activation or insulin gene induction, it seems
unlikely that IRS1 phosphorylation at Ser-307 accounts for the
full inhibitory effect of PA on insulin gene expression. The
shRNA-knockdown experiments, which are consistent with
gene-disruption experiments that have revealed a critical role for
IRS2 in InsR signaling (11), highlighted an important function
for IRS2 in glucose-induced insulin expression and led us to
examine the possibility that JNK also phosphorylates IRS2.
Indeed, we found that IRS2 is an efficient substrate for JNK1,
which phosphorylates it at Thr-348. Based on the location of this
site, we suggest that it is the functional homolog of Ser-307 on
IRS1 and that its phosphorylation is likely to disrupt the
interaction between the PTB motif of IRS2 and activated InsR.
This suggestion is consistent with earlier results, which demon-
strate that treatment of Chinese hamster ovary cells with the
potent JNK activator anisomycin, inhibited insulin-induced ty-
rosine phosphorylation of both IRS1 and IRS2 (5). In addition,
we observed that PA treatment inhibited insulin-induced IRS1-
and IRS2-associated PI3K activity in a JNK-dependent manner
(Figs. 2B and 8).
Strikingly, the JNK docking site, the D domain, is perfectly
conserved between IRS1 and IRS2, and the sequence surround-
ing the JNK phosphoacceptor sites is also quite well conserved,
suggesting that IRS1 and IRS2 have coevolved not only as InsR
substrates and signal transducers but also as targets for JNK-
mediated inhibitory signaling. Thus, JNK activation may be part
of a homeostatic mechanism that controls the output from
activated InsR. Because it had been observed that JNK is
activated in the livers of rats during repeated fasting–refeeding
cycles (30), and because FFA levels are particularly elevated
during fasting, one possibility is that this pathway might have
evolved as negative regulator of insulin signaling during starva-
tion. Because de novo lipogenesis (fatty acid synthesis) is one of
the major effects of insulin, excessive insulin signaling will not
only lower blood glucose below a critical threshold but will also
increase the circulating levels of FFA. Increased levels of
saturated FFA lead to JNK activation, IRS1 and IRS2 SerThr
phosphorylation, and down-regulation of InsR signaling. The
latter results in insulin-stimulated metabolic processes in periph-
eral tissues including de novo lipogenesis. At the same time,
JNK-mediated down-regulation of InsR signaling in pancreatic
-cells would decrease the synthesis and eventual release of
insulin. This hypothesis is consistent with previous studies show-
ing that an adipose tissue-specific InsR knockout protects from
obesity and obesity-induced glucose intolerance (31), whereas a
knockout of the InsR gene in the -cell results in an insulin
secretion defect similar to that in type-2 diabetes (32).
In addition to further explaining the intricate involvement of JNK
in the regulation of insulin signaling, our findings underscore the
importance of JNK inhibition as a therapeutic strategy for preven-
tion of glucose intolerance and increasing both insulin sensitivity
and insulin synthesis. Although this study has focused on saturated
FFAas JNKactivators, other studies have shown that inflammatory
cytokines, such as TNF (33) and endoplasmic reticulum stress
(34), which also inhibit insulin signaling, do so through JNK
activation. Thus, JNK inhibition should provide a general strategy
for increasing insulin sensitivity and availability.
Materials and Methods
Mice and Models of Diabetes. We used male mice of C57BL6J
background including obob and Jnk1/mice. For STZ-induced
diabetes, mice were fasted overnight, followed by i.p. injection of
STZ in pH 4.5 citrate buffer at a concentration of 200mgkg. For
alloxan-induced hyperglycemia, 8-week-old mice fasted for 6 h
were i.p. injected with alloxan in PBS at a concentration of 200
mgkg. Blood glucose was measured before and at 3 and 10 days
after injection. Mice were killed, and their livers were immedi-
ately collected and frozen in liquid nitrogen. For diet-induced
obesity, 6-week-old mice were given a high-fat diet (Diet F3282;
Bioserve, Frenchtown, NJ) for 8 weeks. Liver perfusion was
conducted on 8- to 16-week-old anesthetized mice. The portal
vein was exposed by abdominal incision and cannulated. After a
brief (30 sec) perfusion with sterile PBS, livers were perfused at
2 mlmin for 30 sec with either delipidated BSA (0.5%) or
PA-loaded BSA (0.5 mM PA) in PBS. The perfusion rate was
decreased to 0.5 mlmin, and perfusion continued for 1 h, after
which the liver was isolated and snap-frozen in liquid nitrogen.
Primary Cell Cultures.Mouse islets were isolated as described (35).
Briefly, 8- to 16-week-old mice were killed, and 2.5 ml of 40
mgml collagenase P (Roche, Indianapolis, IN) in Hanks’ bal-
anced salt solution (HBSS) were slowly infused into the common
bile duct. The pancreas was collected and incubated with col-
lagenase solution at 37°C for 13 min with agitation. Digestion
was stopped by addition of ice-cold HBSS–5% FBS. Pancreas
was filtered trough a 400-m mesh, and islets were purified on
a four-layer HBSS–Ficoll gradient. Islets were collected at the
interphases between 11.5–21.5% and 21.5–23%. Islets were
washed twice with HBSS–5% FBS and cultured in RPMI
medium 1640–10% FBS with antibiotics.
Hepatocytes were isolated and cultured as described (36) with
minor modifications. Briefly, mice were anesthetized, and the livers
were perfused with calcium-free HBSS with EGTA (5mM) via the
portal vein, followed by perfusion with HBSS (with calcium)
containing 500 mgliter collagenase (Sigma). Digested livers were
transferred to cold DMEM plus 10% FCS and agitated. The slurry
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was strained and spun at 50  g for 30 sec. Hepatocytes were then
plated in DMEM–10%FCS containing 10 mgliter insulin (Sigma)
on collagen-coated dishes. The next morning, the medium was
replaced with fresh medium without insulin.
Biochemical Assays. JNK solid-state kinase assays using GST-cJun
(1–79) as a substrate were performed as described (37). PI3K
assays and phospho-AKT Ser-473 immunoblots were also per-
formed as described (38). For PI3K assays, 300 g of protein was
immunoprecipitated with the relevant antibodies, and reaction
products were separated on gel 60 TLC plates (Whatman,
Clifton, NJ). IRS1 Ser-307 phosphorylation was assessed by
immunoblotting with antiphospho-IRS1 Ser-307 antibodies (Up-
state Biotechnology, Lake Placid, NY). After stripping, the
membrane was reprobed with total IRS1 antibodies (Upstate
Biotechnology). Binding of IRS2 to JNK1 was assessed as
described for IRS1 binding to JNK1 (3). The source of IRS2 were
lysates of HEK293T cells transfected with pcDNA3IRS2 (38),
provided by Luciano Pirola (University of Lyon, Lyon, France).
To examine IRS2 phosphorylation in vitro, a fragment of IRS2
including the phosphoacceptor site and the D domain was PCR
cloned by using the following primers: forward (5-actgaattcct-
ggcggccacccccccagcagcc-3) and reverse (5-tgctgggaagggtctc-
gagtccctc-3). To convert Thr-348 to Ala, we used a forward
primer (5-actgaattcctggcggccgcccccccagcagcc-3) containing an
Ala instead of a Thr codon at position 348. PCR products were
cloned in pET-41() (Novagen, San Diego, CA) to express
either GSTIRS2JD or GSTIRS2JalaD. Kinase reactions were
performed by using 10 g of partially purified IRS2. To examine
IRS2 phosphorylation in cells, we have cloned IRS2JD and
IRS2JalaD fused to an N-terminal Flag epitope into pcDNA3.
All of the resultant constructs were transfected into HEK293T
cells. Phosphatase inhibitors were added to all samples except
those treated with alkaline phosphatase. Proteins were precip-
itated with 20% trichloracetic acid (TCA) and dissolved in
sample buffer: 9 M urea, 2% Triton X-100, 0.5% ampholytes, 50
mM DTT, and 0.002% bromophenol blue. Isoelectrofocusing
was performed on Zoom Strips (Invitrogen, Carlsbad, CA).
Second-dimension SDSPAGE was performed by using Nu-
PAGE 4–12% Bis-Tris Zoom gels (Invitrogen).
Viral Transductions. Lentiviruses expressing eGFP or JNK1 were
described (39). Primary hepatocytes were infected at MOI  20
transduction units per cell, sufficient to transduce 95% of
hepatocytes. Adenoviruses vectors expressing shIRS1 or shIRS2
were provided by M. Montminy at the Salk Institute for Bio-
logical Studies (La Jolla, CA) (40). Primary mouse islets were
infected at MOI 2,000 plaque-forming units per islet, resulting
in the infection of nearly all of the cells.
S1 Nuclease Protection Assay. S1 nuclease protection was per-





CCTTCcaaagttag-3. The uppercase sequence is complemen-
tary to the target mRNA, and the 3 lowercase sequence is a
random sequence serving as a specificity control.
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